Press release
Competitive Landscape: Key Market Leaders and Emerging Companies in the Targeted Alpha-Therapy Industry
Targeted Alpha-Therapy Market
Projected Growth Outlook for the Targeted Alpha-Therapy Market Size Through 2030
The targeted alpha-therapy market is anticipated to grow rapidly in the coming years, reaching a valuation of $2.25 billion by 2030. This growth corresponds to a strong compound annual growth rate (CAGR) of 17.0%. The surge is driven by multiple factors such as enhanced investments in isotope production infrastructure, wider adoption of personalized radiotherapy approaches, expansion of targeted alpha therapies into diverse medical indications, increased regulatory backing for radiopharmaceuticals, and stronger collaborations between nuclear medicine and oncology specialists. Key trends molding the market include accelerated development of alpha-emitting radiopharmaceuticals, growing utilization of targeted radioligand therapies, a greater emphasis on precision radiation delivery, scaling up isotope manufacturing capacities, and improved integration of targeting molecules in therapy design.
Download a free sample of the targeted alpha-therapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28337&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Top Companies Leading the Targeted Alpha-Therapy Market
Several prominent players dominate the targeted alpha-therapy landscape, including Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., and RadioMedix Inc.
In a notable development in June 2024, AstraZeneca Plc, a pharmaceutical company based in the UK, acquired Fusion Pharmaceuticals Inc., a Canadian biotech firm specializing in targeted alpha-therapy, for an undisclosed sum. This acquisition reflects AstraZeneca's strategic intent to revolutionize cancer care by advancing more precise, next-generation radioconjugate therapies as alternatives to conventional chemotherapy and radiotherapy.
View the full targeted alpha-therapy market report:
https://www.thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Emerging Trends Boosting Growth in the Targeted Alpha-Therapy Market
A significant trend in this market is the focus by leading companies on innovative therapies such as peptide receptor radionuclide therapy (PRRT), which enhances cancer treatment by delivering radioactive isotopes directly to tumor cells while sparing healthy tissues. PRRT uses peptides that bind specifically to receptors abundant on cancer cells, offering improved efficacy and reduced side effects.
For example, in February 2024, RadioMedix Inc., a US biotechnology firm, partnered with Orano Med, another US pharmaceutical company, to develop AlphaMedix (lead-212-Dotamtate). This therapy became the first targeted alpha therapy to receive FDA breakthrough device designation. AlphaMedix targets advanced gastroenteropancreatic neuroendocrine tumors by delivering powerful alpha radiation precisely to cancer cells. The treatment's advantage lies in the high-energy, short-range alpha particles that inflict lethal DNA damage on tumor cells with minimal harm to surrounding healthy tissue. This approach promises an effective alternative for patients who have not responded well to existing beta-emitter therapies.
Detailed Breakdown of Segments in the Targeted Alpha-Therapy Market
The targeted alpha-therapy market is categorized based on several dimensions:
1) Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, and other isotopes.
2) Application Areas: Prostate Cancer, Bone Metastases, Pancreatic Cancer, and other indications.
3) End-User Categories: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma treatment centers, and other users.
Further subsegments include specific therapies under each isotope type, such as:
- Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE
- Radium-223: Radium-223 Dichloride (Xofigo)
- Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab
- Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC
- Other isotopes: Thorium-227, Astatine-211, Terbium-149
This detailed segmentation provides a comprehensive understanding of the market's structure and areas of innovation as targeted alpha-therapy continues to evolve and expand.
New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Competitive Landscape: Key Market Leaders and Emerging Companies in the Targeted Alpha-Therapy Industry here
News-ID: 4597121 • Views: …
More Releases from The Business Research Company
Emerging Growth Patterns Driving Expansion in the Toxoplasmosis Treatment Drugs …
The toxoplasmosis treatment drugs market is poised for considerable expansion over the coming years. With ongoing innovations in medication and growing patient needs, this sector is set to experience meaningful progress. Let's explore the current market scale, influential factors, key players, notable trends, and important segments shaping this industry.
Projected Market Value and Growth of the Toxoplasmosis Treatment Drugs Market
The market for toxoplasmosis treatment drugs is forecasted to reach…
Future Prospects: Key Trends Shaping the Topical Drugs Contract Development and …
The topical drugs contract development and manufacturing organization (CDMO) market is poised for substantial expansion over the coming years. Driven by technological advancements and evolving pharmaceutical needs, this sector is set to become increasingly vital in the drug development landscape. Let's explore the market's projected growth, key players, emerging trends, and segmentations shaping its future through 2030.
Projected Growth Trajectory of the Topical Drugs CDMO Market
The topical drugs CDMO…
Market Trend Insights: The Impact of Emerging Developments on the Skin Health Su …
The skin health supplements and treatment sector is poised for significant expansion as consumer interest in maintaining and improving skin quality continues to rise. Advancements in product formulation and delivery, along with growing accessibility through digital platforms, are expected to drive this market's evolution over the next several years.
Anticipated Market Size for Skin Health Supplements and Treatment by 2030
The market for skin health supplements and treatments is projected…
Emerging Sub-Segments Transforming the Subcutaneous Immunoglobulin (SCIG) Market …
The subcutaneous immunoglobulin (SCIG) market is on the brink of substantial expansion as it evolves to meet growing healthcare demands. Increasing acceptance of home-based therapies and advancements in treatment technology are reshaping this sector, highlighting its importance for patients with immune-related conditions. Let's explore the market's projected valuation, key players, emerging trends, and detailed segment analysis.
Subcutaneous Immunoglobulin Market Size and Growth Outlook
The SCIG market is anticipated to experience…
More Releases for Targeted
Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…
Dark Truth Behind Targeted Violence
Intimidation and cyberbullying public bullying the (target)victims selected into committing the violent criminal acts if the victims mentality was broken.
The perpetrators are small fraud groups organizing misinformation with false profiles for the public to participate with public bullying while the groups stalk the victim.
San Diego California 2021-2024 plot failed federal agents on standby monitoring the targets failed at there duties of integrity while presidential elections push towards Nov 5 San…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Targeted Email Leads: Pioneering a New Era in Email Marketing with High-Quality, …
GREENSBORO, NC - 15 August 2024 - In the rapidly evolving digital landscape, one company is setting new standards in email marketing. Targeted Email Leads, a trailblazer in the provision of precision-targeted email lists, is offering meticulously cleaned and verified lists that cater to a wide range of applications, from B2B communications to consumer engagement and interest groups.
What sets Targeted Email Leads apart is their rigorous verification process. Each…
Tetravalent Antibody as Cancer Targeted Therapy
The advent of tetravalent antibodies marks a significant breakthrough in cancer targeted therapy, offering a sophisticated approach to tackling the complex and heterogeneous nature of tumors. These antibodies, engineered to bind to four distinct antigens or epitopes simultaneously, provide enhanced specificity and efficacy, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Cancer is a multifaceted disease characterized by diverse cell populations within a…
Targeted Advertising Solutions Market - Rising Demand from the Providers of Targ …
The rising popularity of digital channels such as mobile and online for media and entertainment, and communications, coupled with their capability to identify and benefit from tracking customer behavior accurately, have created major interest and increasing investments by advertisers on targeted advertising.
Download PDF Brochure For Future Advancements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47862
Organizations making an entry into the advertising value network need to effectively educate, engage, and create alertness to the advantages of targeted…
